



DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfnv.gov>

NOTICE OF PUBLIC MEETING – SILVER STATE SCRIPTS BOARD

AGENDA

Date of Publication: August 27, 2019

Date and Time of Meeting: September 26, 2019 at 1:00 PM

Name of Organization: The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: Springs Preserve
333 S. Valley View Blvd.
Las Vegas, Nevada 89107

Please check with staff to verify room location.

There will not be a North Location for this meeting.

Webinar Registration: <https://optum.webex.com/optum/onstage/g.php?MTID=e92408862a87476dc413f27f0e9f41a5e>

OR

www.webex.com, select “Join,” enter Meeting Number 649 066 646, your name and email and then select, “Join.”

A Password should not be necessary, but if asked, enter, “Medicaid1!”

OR

Audio Only: (763) 957-6300
Event Number: 649 066 646

Follow the instructions that appear on your screen to join the teleconference. Audio will also be broadcast over the internet (VoIP).

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Tanya Benitez at: (775) 684-3722 or email Tbenitez@dchfp.nv.gov in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Items may be taken out of order.

Items may be combined for consideration by the public body.

Items may be pulled or removed from the agenda at any time.

Public comment is limited to five minutes per individual, organization or agency, but may be extended at the discretion of the Chairperson.

1:00 PM – 2:00 PM – Closed Executive Session

Pursuant to Nevada Revised Statutes (NRS) 422.405(4), as amended by Senate Bill 378 during the 80th Legislative session, the Board intends to hold a closed session for discussions between the Division of Healthcare Financing and Policy (DHCFP), OptumRx and the Silver State Scripts Board regarding the methodology and selection of preferred agents on the Nevada Medicaid Preferred Drug List (PDL).

2:00 PM – 5:00 PM – Public Meeting (Open Session)

AGENDA

- 1. Call to Order and Roll Call**
- 2. Public Comment**
- 3. Old Business**
 - a. **For Possible Action:** Review and Approve Meeting Minutes from June 27, 2019.
- 4. New Business**
 - a. Status Update by the DHCFP.
 - b. **For Possible Action:** Board Discussion and Approval of Existing PDL as Established by the Nevada Medicaid Pharmacy and Therapeutics Committee.
 - c. **Annual Review – Established Drug Classes Being Reviewed Due to the Release of New Drugs**
 1. Cardiovascular Agents: Antihypertensive Agents (Calcium-Channel Blockers), Antilipemics (HMG-CoA Reductase Inhibitors (Statins))

- a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL
2. Psychotropic Agents: Attention Deficit Hyperactivity Disorder (ADHD) Agents, Psychostimulants (Narcolepsy Agents)
- a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL
- d. **Annual Review – Established Drug Classes**
1. Analgesics: Opiate Agonists (Opiate Agonists - Abuse Deterrent)
- a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL
2. Anti-infective Agents: Aminoglycosides (Inhaled Aminoglycosides), Antivirals, Anti-hepatitis Agents (Polymerase Inhibitors/Combination Products), Antivirals (Influenza Agents), Macrolides
- a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL

3. Biologic Response Modifiers: Immunomodulators (Targeted Immunomodulators)
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 1. Approval of drugs for Inclusion on the PDL

4. Cardiovascular Agents: Antihypertensive Agents (Angiotensin II Receptor Antagonists), Vasodilators (Oral), Antilipemics (Omega-3 Fatty Acids)
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 1. Approval of drugs for Inclusion on the PDL

5. Dermatological Agents: Topical Anti-infectives (Topical Antivirals, Topical Scabicides), Topical Anti-inflammatory Agents (Immunomodulators: Topical)
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 1. Approval of drugs for Inclusion on the PDL

6. Gastrointestinal Agents: Antiemetics (Miscellaneous), Antiulcer Agents (Proton Pump Inhibitors [PPIs]), Gastrointestinal Anti-inflammatory Agents
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP

- e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL

- 7. Hematological Agents: Erythropoiesis-Stimulating Agents
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL

- 8. Hormones and Hormone Modifiers: Antidiabetic Agents (Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Incretin Mimetics, Insulins [Vials, Pens and Inhaled], Meglitinides, Sodium-Glucose Co-Transporter 2 [SGLT2] Inhibitors, Sulfonylureas, Thiazolidinediones)
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL

- 9. Neurological Agents: Anti-Migraine Agents (Calcitonin Gene-Related Peptide [CGRP] Receptor Antagonists, Serotonin-Receptor Agonists)
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL

- 10. Psychotropic Agents: Antipsychotics (Atypical Antipsychotics – Oral)
 - a. Public Comment
 - b. Drug Class Review Presentation – OptumRx

- c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL
11. Respiratory Agents: Long-Acting/Maintenance Therapy
- a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL
12. Toxicology Agents: Substance Abuse Agents
- a. Public Comment
 - b. Drug Class Review Presentation – OptumRx
 - c. **For Possible Action:** Board Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - d. Presentation of Recommendations for PDL Inclusion by OptumRx and the DHCFP
 - e. **For Possible Action:** Board Discussion and Action
 - 1. Approval of drugs for Inclusion on the PDL
- e. **Annual Review – Drug Classes Without Proposed Changes, For Possible Action**
- 1. Public Comment
 - 2. Presentation of Recommendation for PDL Inclusion by OptumRx and the DHCFP without Changes.
 - a. Analgesics: Analgesic/Miscellaneous (Neuropathic Pain/Fibromyalgia Agents, Tramadol and Related Drugs), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) – Oral,
 - b. Antihistamines: H1 blockers (Non-Sedating H1 Blockers)
 - c. Anti-Infective Agents: Antivirals (Alpha Interferons), Anti-Hepatitis Agents (Ribavirins), Anti-Herpetic Agents, Cephalosporins (Second-Generation Cephalosporins, Third-Generation Cephalosporins), Quinolones (Quinolones - 2nd Generation, Quinolones - 3rd Generation)
 - d. Autonomic Agents: Sympathomimetics (Self-Injectable Epinephrine)

- e. Biologic Response Modifiers: Multiple Sclerosis Agents (Injectable, Oral, Specific Symptomatic Treatment)
- f. Cardiovascular Agents: Antihypertensive Agents (Angiotensin-Converting Enzyme Inhibitors [ACE Inhibitors], Beta-Blockers, Vasodilators [Inhaled], Antilipemics (Bile Acid Sequestrants, Absorption Inhibitors, Fibric Acid Derivatives, Niacin Agents)
- g. Dermatological Agents: Antipsoriatic Agents (Topical Vitamin D Analogs, Topical Analgesics, Topical Anti-infectives [Acne Agents: Topical, Benzoyl Peroxide, Antibiotics and Combination Products]), Topical Anti-infectives (Impetigo Agents: Topical), Topical Antineoplastics (Topical Retinoids)
- h. Electrolytic and Renal Agents: Phosphate Binding Agents
- i. Gastrointestinal Agents: Antiemetics (Serotonin-receptor antagonists/Combo), Antiulcer Agents (H2 blockers), Functional Gastrointestinal Disorder Drugs, Gastrointestinal Enzymes
- j. Genitourinary Agents: Benign Prostatic Hyperplasia (BPH) Agents (5-Alpha Reductase Inhibitors, Alpha-Blockers), Bladder Antispasmodics
- k. Hematological Agents: Anticoagulants (Injectable, Oral), Platelet Inhibitors
- l. Hormones and Hormone Modifiers: Androgens, Antidiabetic Agents (Alpha-Glucosidase Inhibitors/Amylin Analogs/Misc.), Pituitary Hormones (Growth Hormone Modifiers)
- m. Monoclonal Antibodies for the Treatment of Respiratory Conditions
- n. Musculoskeletal Agents: Antigout Agents, Bone Resorption Inhibitors (Bisphosphonates, Nasal Calcitonins), Restless Leg Syndrome Agents, Skeletal Muscle Relaxants
- o. Neurological Agents: Alzheimer's Agents, Anticonvulsants (Barbiturates, Benzodiazepines, Hydantoins), Antiparkinsonian Agents (Non-Ergot Dopamine Agonists)
- p. Ophthalmic Agents: Antiglaucoma Agents, Ophthalmic Antihistamines, Ophthalmic Anti-Infectives (Ophthalmic Macrolides, Ophthalmic Quinolones), Ophthalmic Anti-Infective/Anti-Inflammatory Combinations, Ophthalmic Anti-Inflammatory Agents (Ophthalmic Corticosteroids, Ophthalmic Nonsteroidal Anti-inflammatory Drugs [NSAIDs], Ophthalmics for Dry Eye Disease
- q. Otic Agents: Otic Anti-infectives (Otic Quinolones)
- r. Psychotropic Agents: Antidepressants (Other, Selective Serotonin Reuptake Inhibitors [SSRIs]), Anxiolytics, Sedatives, and Hypnotics
- s. Respiratory Agents: Nasal Antihistamines, Respiratory Anti-inflammatory Agents (Leukotriene Receptor Antagonists, Nasal Corticosteroids, Phosphodiesterase Type 4 Inhibitors), Short-Acting/Rescue Therapy
- t. Toxicology Agents: Antidotes (Opiate Antagonists)

3. **For Possible Action:** Board Discussion and Action

- a. Approval of drugs for Inclusion on the PDL

f. **Report by OptumRx on New Drugs to Market, New Generic Drugs to Market, and New Line Extensions**

g. Presentation, Discussion and Possible Adoption of Updated Silver State Script Board Bylaws for Possible Action

1. Public Comment on Bylaws
2. Presentation by DHCFP of updates to Bylaws
3. Discussion by Board and review of updates to Bylaws
4. Proposed adoption of updated Bylaws

h. Closing Discussion

1. Public comments on any subject
2. Date and location of the next meeting
3. Adjournment

Notice of this public meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP Web site at <http://dhcftp.nv.gov> and notice.nv.gov/. The agenda posting of this meeting can be viewed at the follow locations: Carson City Central Office; Las Vegas District Office; Reno District Office; Elko District Office; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Esmeralda County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the proposal will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 101, Carson City, Nevada 89701 at least three days prior to the public workshop.

All persons that have requested in writing to receive the public meeting agenda have been duly notified by mail or e-mail.

Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the DHCFP, in writing, at 1100 East William Street, Suite 101, Carson City, or call Tanya Benitez at (775) 684-3730, as soon as possible, or e-mail at tbenitez@dhcftp.nv.gov.
